H7N9病例死亡率达40%, 人感染病例陆续发生，疾病防控形势依然严峻。研究表明，H7亚型的病毒和灭活病毒疫苗诱导中和抗体的能力并不强，但是以中和表位为基础的的亚单位疫苗却能有效地诱导中和抗体的产生，因此，血凝素蛋白中和表位的鉴定，有利于亚单位疫苗的设计和中和抗体的诱导。我们对7型血凝素蛋白（HA7）抗原表位筛查的前期结果发现，H7N9患者体内有高水平的HA7胞内域（CT）特异性的抗体，其是否为中和表位有待进一步确认。 那么HA7的中和表位有哪些？这些中和表位能否有效地诱导动物产生中和抗体？能否保护小鼠免受病毒攻击？本研究拟采用HA7线性和构象表位筛选技术， 对HA7上的中和表位进行系统筛查和验证，并通过多样本相关性分析确定中和表位，然后检验中和表位蛋白的诱导小鼠产生中和抗体的能力和保护小鼠免受流感病毒攻击的潜力，为H7N9流感病毒亚单位疫苗的设计提供参考，为治疗性单克隆中和抗体的研发提供

Fatality rate of H7N9 infection cases reached as high as 40%. As no effective therapy and vaccine available, the public health control of the disease is still under pressure. It have been reported that H7 virus and inactivated virus vaccine are poor inducers of neutralizing antibodies, however, neutralizing epitope based subunit vaccine induce high titer of neutralizing antibodies. Our previous study found that high level of HA7 cytoplasmic domain (CT) specific antibody was induced among H7N9 infected patients, whether it is a neutralizing epitope is unclear. What are the neutralizing epitopes on type 7 hemaglutinin? Whether they can induce neutralizing antibody in mice and protect mice from virus attack? To solve these questions, present study will use linear and conformational epitope screening technology to identify neutralizing epitope of H7N9 patient serum on hemaglutinin, investigate their potential on inducing neutralizing antibody. The accomplishment of this project will provide reference for the design of H7N9 subunit vaccine and target for therapeutic monoclonal antibody development.